Growth-Minded AMAG Pharma Closes $201.2M Stock Offering
Amag Pharmaceuticals Inc. has completed an upsized $201.2 million stock offering, raising money for product lineup expansion and possibly acquisitions, in a transaction guided by Goodwin Procter LLP and Davis Polk...To view the full article, register now.
Already a subscriber? Click here to view full article